Clinical trial
Teplizumab in Pediatric Stage 2 Type 1 Diabetes
NCT05757713
Study timeline
Study start (actual)2023-07-25Date precision: day
Registry last updated2026-09-29
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Diabetes Mellitus, Type 1unresolved
Interventions
teplizumabBIOLOGICAL
Sponsors & collaborators
Sanofilead sponsor
Mapped research locations
PhiladelphiaPennsylvania, United States1NashvilleTennessee, United States1San FranciscoCalifornia, United States1IndianapolisIndiana, United States1AuroraColorado, United States1New HavenConnecticut, United States1BuffaloNew York, United States1TacomaWashington, United States1Sioux FallsSouth Dakota, United States1ColumbusGeorgia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05757713 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.